Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a dynamic and growing pharmaceutical company dedicated to developing, manufacturing, and distributing a diverse portfolio of high-quality generic and specialty pharmaceutical products. With a strong focus on quality, customer service, and innovation, Amneal strives to provide accessible and affordable medicines to patients worldwide. Their key therapeutic areas include central nervous system disorders, endocrinology, and parasitic infections, alongside a robust generics business.
The headquarters serves as the central hub for Amneal's global operations, including corporate leadership, strategic planning, research and development oversight, finance, legal, and administrative functions.
A modern corporate facility designed to foster collaboration and innovation. While specific unique architectural highlights are not widely publicized, it is equipped with state-of-the-art amenities typical of a leading pharmaceutical company's headquarters.
The work culture at Amneal's headquarters is characterized by a fast-paced, entrepreneurial spirit with a strong emphasis on quality, integrity, and teamwork. Employees are driven by the mission to make essential medicines more accessible.
The Bridgewater headquarters is strategically important due to its location within New Jersey's rich pharmaceutical ecosystem, providing access to a skilled talent pool, research institutions, and industry partners. It anchors Amneal's U.S. and international operations.
Amneal Pharmaceuticals supports global functions including research and development, manufacturing, packaging, distribution, and commercial operations. Key operational hubs are located in North America (USA), Asia (primarily India), and Europe (Ireland), enabling the company to serve markets worldwide with a broad portfolio of generic and specialty medicines.
400 Crossing Boulevard
Bridgewater
New Jersey
USA
Address: Multiple sites including SEZ, Village: Chharodi, Ahmedabad, Gujarat, India (example address, specific addresses vary by facility)
Serves as a critical center for cost-effective research, development, and high-volume manufacturing for diverse international markets.
Address: 1 New England Avenue, Piscataway, NJ 08854, USA (example of one Piscataway site)
Strengthens Amneal's U.S. manufacturing footprint and R&D capabilities, enabling a robust supply of products to American patients and healthcare providers.
Address: Amneal Ireland Limited, Cahir Road, Cashel, Co. Tipperary, Ireland
Serves as a strategic European base for manufacturing and development, particularly for specialized drug delivery systems, supporting Amneal's expansion in European and other global markets.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Amneal Pharmaceuticals' leadership includes:
Amneal Pharmaceuticals has been backed by several prominent investors over the years, including:
Over the last 12 months (approx. May 2023 - May 2024), Amneal Pharmaceuticals has seen key leadership appointments, particularly strengthening its financial and commercial teams. Notable changes include a new Chief Financial Officer and a new Chief Commercial Officer for the Specialty division, indicating a focus on strategic growth in these areas.
Discover the tools Amneal Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Amneal Pharmaceuticals commonly uses a few standard email formats for its employees. The most prevalent formats are typically a combination of the employee's first name initial and last name, or first name and last name separated by a dot.
[first_initial][last]@amneal.com (e.g., jdoe@amneal.com) or [first].[last]@amneal.com (e.g., jane.doe@amneal.com)
Format
jdoe@amneal.com
Example
85%
Success rate
Amneal Pharmaceuticals IR • May 9, 2024
Amneal reported its financial results for the first quarter of 2024, highlighting revenue growth and progress on its strategic initiatives. Key discussion points included performance in Generics, Specialty, and AvKARE segments....more
Amneal Pharmaceuticals IR • May 7, 2024
Amneal announced it received U.S. Food and Drug Administration (FDA) approval for PEMRYDI RTU™ (pemigatinib), the first and only FDA-approved ready-to-use FGFR2 inhibitor for pretreated, unresectable locally advanced or metastatic cholangiocarcinoma....more
Amneal Pharmaceuticals IR • February 28, 2024
Amneal received Abbreviated New Drug Application (ANDA) approval from the U.S. FDA for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution, a generic version of Combivent Respimat®, for treatment of COPD....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Amneal Pharmaceuticals, are just a search away.